Wu X - Search Results

1

MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways.

Lou Z, Minter-Dykhouse K, Wu X, Chen J. Lou Z, et al. Among authors: wu x. Nature. 2003 Feb 27;421(6926):957-61. doi: 10.1038/nature01447. Nature. 2003. PMID: 12607004

2

A DNA damage-regulated BRCT-containing protein, TopBP1, is required for cell survival.

Yamane K, Wu X, Chen J. Yamane K, et al. Among authors: wu x. Mol Cell Biol. 2002 Jan;22(2):555-66. doi: 10.1128/MCB.22.2.555-566.2002. Mol Cell Biol. 2002. PMID: 11756551 Free PMC article.

3

Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis.

Wu X, Chen J. Wu X, et al. J Biol Chem. 2003 Sep 19;278(38):36163-8. doi: 10.1074/jbc.M303795200. Epub 2003 Jul 9. J Biol Chem. 2003. PMID: 12855706 Free article.

4

Characterization of CHEK2 mutations in prostate cancer.

Wu X, Dong X, Liu W, Chen J. Wu X, et al. Hum Mutat. 2006 Aug;27(8):742-7. doi: 10.1002/humu.20321. Hum Mutat. 2006. PMID: 16835864

5

Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair.

Wu X, Mondal G, Wang X, Wu J, Yang L, Pankratz VS, Rowley M, Couch FJ. Wu X, et al. Among authors: wu j. Cancer Res. 2009 Jul 1;69(13):5531-6. doi: 10.1158/0008-5472.CAN-08-4834. Epub 2009 Jun 23. Cancer Res. 2009. PMID: 19549900 Free PMC article.

6

Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens.

Hawse JR, Subramaniam M, Cicek M, Wu X, Gingery A, Grygo SB, Sun Z, Pitel KS, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC. Hawse JR, et al. Among authors: wu x. PLoS One. 2013;8(1):e54613. doi: 10.1371/journal.pone.0054613. Epub 2013 Jan 28. PLoS One. 2013. PMID: 23382923 Free PMC article.

7

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.

Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. Wu X, et al. Cancer Res. 2009 Mar 1;69(5):1722-7. doi: 10.1158/0008-5472.CAN-08-3933. Epub 2009 Feb 24. Cancer Res. 2009. PMID: 19244106

8

ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.

Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR. Reese JM, et al. Among authors: wu x. BMC Cancer. 2014 Oct 7;14:749. doi: 10.1186/1471-2407-14-749. BMC Cancer. 2014. PMID: 25288324 Free PMC article.

9

Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody.

Wu X, Subramaniam M, Negron V, Cicek M, Reynolds C, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR. Wu X, et al. J Cell Biochem. 2012 Feb;113(2):711-23. doi: 10.1002/jcb.23443. J Cell Biochem. 2012. PMID: 22095450 Free PMC article.

10

Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.

Wu X, Subramaniam M, Grygo SB, Sun Z, Negron V, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR. Wu X, et al. Breast Cancer Res. 2011 Mar 10;13(2):R27. doi: 10.1186/bcr2844. Breast Cancer Res. 2011. PMID: 21392396 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58,853 results

Search Page

Filters